A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
2022-RA-919-ESGO A pilot study of interval cytoreductive surgery and HIPEC for advanced epithelial ovarian cancer in the UK
2022
Ovarian cancer
unpublished
Preserved Fulltext
difference in PFS was observed between treatment arm in patients without HRD positive tumors (HR, 0.92; 95% CI, 0.59-1.43; P=0.69). The effect of the interaction between olaparib and HRD status on PFS, in the interim study, was similar for the two stratification methods (P=0.20). Conclusion The interim results of SOPHiA DDM Dx HRD Solution evaluation study support the value of lpWGS data for patient stratification, making it suitable for HRD testing in the clinical setting.
doi:10.1136/ijgc-2022-esgo.592
fatcat:mznv22qsybe5jaqoedbhdbuhva